N-phenylacridin-9-amine derivative having anticancer activity on the different human cancer cell like; human nasopharyngeal carcinoma [HONE-1] cell line, human adenocarcinoma [colon and rectal] tumor [HT-29] cell line, human brain tumor [DBTRG] cell line, gastric carcinoma TSGH, hepatoma liver hepa-G2, mouth carcinoma KB, lung adenocarcinoma H460, breast adenocarcinoma MX-1 and MCF-7 cell line and it’s significant cytotoxic activity against human leukemic HL-60 cell growth. N-phenylacridin-9-amine derivative exhibit both in-vivo as well as in-vitro potent antitumor activity. The alkylcarbamates of the N-phenylacridin-9-amine is more effective than their corresponding parent N-phenylacridin-9-amine derivatives. The cytotoxic activity of the N-phenylacridin-9-amine ethylcarbamates is decreased with increasing length and size of the alkyl function. It’s having also drug-DNA binding affinity which affected the antitumor activity of 9-anilinoacridines. These compound having higher cytotoxic activity due to high lipophilicity. We were used 24 compounds and those pIC50 activities on the HONE-1, HT-29 and DBTRG cell line for the QSAR study. Here the QSAR studies of N-phenylacridin-9-amine analogues were performed by using software CHEM-DRAW ULTRA-8.0, OPENBABLE-2.2.1, DRAGON, VALSTAT. We are considering here four model equations for QSAR study. All models question were validated by the VALSTAT software.
Loading....